Early-Stage Esophageal Cancer Might Not Favor Endoscopic Resections
the Cancer Therapy Advisor take:
Patients with localized, early-stage esophageal cancer may undergo endoscopic esophageal resection, which uses a small camera attached to a flexible tube.
This instrument allows little to no distraction to the body while navigating to specific locations throughout the gastrointestinal tract. The surgeon then carries out an esophageal surgical resection to remove a small section of the patient’s esophagus and reconnect the remaining sections of the digestive tract.
Recently, there has been an increase of endoscopic resections over surgical resections; however, according to a study published in the Journal of the National Cancer Institute, an endoscopic resection may not be the best treatment for patients with localized, early-stage esophageal cancer. Senior author David J. Bentrem, MD, and researchers from Northwestern Medicine found that the more invasive, traditional surgical resection had an 87.6% 5-year survival rate, compared to the 76% 5-year survival rate for patients who underwent the less-invasive endoscopic resection.
Results indicated that esophageal resection increased for patients with T1a cancers from 19% in 2004 to 53% in 2010. For patients with T1b cancers, which are more mature and more likely to spread to at least one lymph node compared with T1a cancers, esophageal resection increased from 6.6% in 2004 to 20.9% in 2010.
A new study sheds light on the risks with the growing popularity of endoscopic resection.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer